학술논문
성인 과체중 또는 비만 환자에서 GLP-1 수용체 작용제의 유효성 및 안전성 평가: 체계적 문헌고찰 및 베이지안 네트워크 메타분석
이용수 20
- 영문명
- Efficacy and Safety of GLP-1 Receptor Agonist for Adults with Overweight and Obesity: A Systematic Review and Bayesian Network Meta-Analysis of Randomized Controlled Trials
- 발행기관
- 대한약학회
- 저자명
- 박지영(Ji-young Park) 김혜린(Hye-Lin Kim) 권순홍(Sun-Hong Kwon) 이의경(Eui-Kyung Lee)
- 간행물 정보
- 『약학회지』제69권 제3호(2025년), 240~255쪽, 전체 16쪽
- 주제분류
- 의약학 > 기타의약학
- 파일형태
- 발행일자
- 2025.06.30

국문 초록
This systematic review and Bayesian network meta-analysis (NMA) evaluated the benefits and harms of glucagonlike peptide-1 receptor agonists (GLP-1 RAs) for adults with overweight and obesity. Randomized controlled trials (RCTs) reporting efficacy and safety outcomes were identified through PubMed, Embase, and CENTRAL up to February 2024. Bayesian NMA was conducted using R software (ver. 4.4.0), and the study was registered with PROSPERO (CRD42024522544). Of 6,007 identified articles, 60 RCTs were included. All GLP-1 RAs significantly improved weight loss and waist circumference compared to placebo. Retatrutide showed the greatest weight reduction compared to liraglutide (mean difference [MD]: -11.86%, 95% CrI: -15.04 to -8.66) and semaglutide (MD: -7.34%, -10.42 to -4.21), with higher odds of achieving ≥5% weight reduction (odds ratios [ORs]: 7.29 and 3.68, respectively). Retatrutide also had a higher risk of treatment discontinuation due to adverse events compared to semaglutide (risk ratio [RR]: 3.92, 1.73 to 10.94), tirzepatide (RR: 3.65, 1.55 to 10.31), and liraglutide (RR: 3.57, 1.57 to 9.96). No significant differences in discontinuation rates were observed among tirzepatide, liraglutide, and semaglutide. These findings highlight the efficacy of GLP-1 RAs in weight management, with variations in safety profiles requiring consideration in clinical decision-making.
영문 초록
목차
서 론(Introduction)
방 법(Methods)
결 과(Results)
고 찰(Discussion)
결 론(Conclusion)
Conflict of Interest
References
해당간행물 수록 논문
참고문헌
최근 이용한 논문
교보eBook 첫 방문을 환영 합니다!
신규가입 혜택 지급이 완료 되었습니다.
바로 사용 가능한 교보e캐시 1,000원 (유효기간 7일)
지금 바로 교보eBook의 다양한 콘텐츠를 이용해 보세요!
